nodes	percent_of_prediction	percent_of_DWPC	metapath
Remifentanil—Postoperative complications NOS—Capecitabine—esophageal cancer	0.0879	0.0882	CcSEcCtD
Remifentanil—Post procedural complication—Capecitabine—esophageal cancer	0.0777	0.0779	CcSEcCtD
Remifentanil—Blood in stool—Capecitabine—esophageal cancer	0.0446	0.0448	CcSEcCtD
Remifentanil—Shivering—Capecitabine—esophageal cancer	0.0197	0.0197	CcSEcCtD
Remifentanil—Haematochezia—Capecitabine—esophageal cancer	0.0182	0.0182	CcSEcCtD
Remifentanil—Rales—Capecitabine—esophageal cancer	0.0178	0.0179	CcSEcCtD
Remifentanil—Pneumothorax—Capecitabine—esophageal cancer	0.0147	0.0148	CcSEcCtD
Remifentanil—Lymphopenia—Capecitabine—esophageal cancer	0.0143	0.0144	CcSEcCtD
Remifentanil—Rales—Methotrexate—esophageal cancer	0.0133	0.0133	CcSEcCtD
Remifentanil—Pericarditis—Methotrexate—esophageal cancer	0.0126	0.0126	CcSEcCtD
Remifentanil—Rhinorrhoea—Cisplatin—esophageal cancer	0.0123	0.0123	CcSEcCtD
Remifentanil—Respiratory distress—Capecitabine—esophageal cancer	0.0115	0.0116	CcSEcCtD
Remifentanil—Ileus—Capecitabine—esophageal cancer	0.0103	0.0104	CcSEcCtD
Remifentanil—Pain—Carboplatin—esophageal cancer	0.0103	0.0104	CcSEcCtD
Remifentanil—Hiccups—Cisplatin—esophageal cancer	0.00993	0.00997	CcSEcCtD
Remifentanil—Haemoptysis—Capecitabine—esophageal cancer	0.00989	0.00993	CcSEcCtD
Remifentanil—Hyperkalaemia—Cisplatin—esophageal cancer	0.00976	0.00979	CcSEcCtD
Remifentanil—Pleural effusion—Capecitabine—esophageal cancer	0.00956	0.00959	CcSEcCtD
Remifentanil—Ventricular fibrillation—Capecitabine—esophageal cancer	0.00956	0.00959	CcSEcCtD
Remifentanil—Body temperature increased—Carboplatin—esophageal cancer	0.00955	0.00958	CcSEcCtD
Remifentanil—Coagulopathy—Capecitabine—esophageal cancer	0.00941	0.00944	CcSEcCtD
Remifentanil—Myocardial ischaemia—Capecitabine—esophageal cancer	0.00911	0.00914	CcSEcCtD
Remifentanil—Rhinorrhoea—Capecitabine—esophageal cancer	0.00904	0.00907	CcSEcCtD
Remifentanil—Hypoxia—Methotrexate—esophageal cancer	0.00858	0.00861	CcSEcCtD
Remifentanil—Musculoskeletal stiffness—Capecitabine—esophageal cancer	0.00816	0.00819	CcSEcCtD
Remifentanil—Gastrooesophageal reflux disease—Capecitabine—esophageal cancer	0.00811	0.00813	CcSEcCtD
Remifentanil—Ventricular extrasystoles—Capecitabine—esophageal cancer	0.00811	0.00813	CcSEcCtD
Remifentanil—Nasal congestion—Cisplatin—esophageal cancer	0.00792	0.00794	CcSEcCtD
Remifentanil—Amnesia—Cisplatin—esophageal cancer	0.00768	0.0077	CcSEcCtD
Remifentanil—Hiccups—Capecitabine—esophageal cancer	0.00732	0.00735	CcSEcCtD
Remifentanil—Pleural effusion—Methotrexate—esophageal cancer	0.00712	0.00714	CcSEcCtD
Remifentanil—Urinary incontinence—Capecitabine—esophageal cancer	0.00707	0.00709	CcSEcCtD
Remifentanil—Hypokalaemia—Cisplatin—esophageal cancer	0.00656	0.00658	CcSEcCtD
Remifentanil—Nasopharyngitis—Cisplatin—esophageal cancer	0.00645	0.00647	CcSEcCtD
Remifentanil—Apnoea—Methotrexate—esophageal cancer	0.00643	0.00645	CcSEcCtD
Remifentanil—Sleep disorder—Capecitabine—esophageal cancer	0.00614	0.00616	CcSEcCtD
Remifentanil—Hepatic function abnormal—Capecitabine—esophageal cancer	0.00608	0.0061	CcSEcCtD
Remifentanil—Musculoskeletal stiffness—Methotrexate—esophageal cancer	0.00608	0.0061	CcSEcCtD
Remifentanil—Abdominal discomfort—Cisplatin—esophageal cancer	0.00598	0.00599	CcSEcCtD
Remifentanil—Oliguria—Methotrexate—esophageal cancer	0.00592	0.00593	CcSEcCtD
Remifentanil—Amnesia—Capecitabine—esophageal cancer	0.00566	0.00568	CcSEcCtD
Remifentanil—Atrial fibrillation—Capecitabine—esophageal cancer	0.00561	0.00563	CcSEcCtD
Remifentanil—Renal impairment—Capecitabine—esophageal cancer	0.00559	0.0056	CcSEcCtD
Remifentanil—Renal failure—Cisplatin—esophageal cancer	0.00546	0.00548	CcSEcCtD
Remifentanil—Bradycardia—Cisplatin—esophageal cancer	0.00508	0.00509	CcSEcCtD
Remifentanil—Urinary retention—Capecitabine—esophageal cancer	0.00505	0.00507	CcSEcCtD
Remifentanil—Cardiac arrest—Capecitabine—esophageal cancer	0.00505	0.00507	CcSEcCtD
Remifentanil—Pulmonary oedema—Methotrexate—esophageal cancer	0.00485	0.00487	CcSEcCtD
Remifentanil—Hypokalaemia—Capecitabine—esophageal cancer	0.00484	0.00485	CcSEcCtD
Remifentanil—Visual impairment—Cisplatin—esophageal cancer	0.00481	0.00482	CcSEcCtD
Remifentanil—Nasopharyngitis—Capecitabine—esophageal cancer	0.00475	0.00477	CcSEcCtD
Remifentanil—Flushing—Cisplatin—esophageal cancer	0.00463	0.00464	CcSEcCtD
Remifentanil—Cardiac disorder—Cisplatin—esophageal cancer	0.00463	0.00464	CcSEcCtD
Remifentanil—Dysphagia—Capecitabine—esophageal cancer	0.00459	0.00461	CcSEcCtD
Remifentanil—Bronchospasm—Capecitabine—esophageal cancer	0.00452	0.00453	CcSEcCtD
Remifentanil—Immune system disorder—Cisplatin—esophageal cancer	0.00451	0.00452	CcSEcCtD
Remifentanil—Mediastinal disorder—Cisplatin—esophageal cancer	0.0045	0.00451	CcSEcCtD
Remifentanil—Arrhythmia—Cisplatin—esophageal cancer	0.00446	0.00447	CcSEcCtD
Remifentanil—Bronchitis—Capecitabine—esophageal cancer	0.00442	0.00443	CcSEcCtD
Remifentanil—Abdominal discomfort—Capecitabine—esophageal cancer	0.0044	0.00442	CcSEcCtD
Remifentanil—Erythema—Cisplatin—esophageal cancer	0.00434	0.00436	CcSEcCtD
Remifentanil—Dysuria—Capecitabine—esophageal cancer	0.0043	0.00431	CcSEcCtD
Remifentanil—Visual disturbance—Methotrexate—esophageal cancer	0.00418	0.00419	CcSEcCtD
Remifentanil—Hyperglycaemia—Capecitabine—esophageal cancer	0.00414	0.00416	CcSEcCtD
Remifentanil—Pneumonia—Capecitabine—esophageal cancer	0.00412	0.00413	CcSEcCtD
Remifentanil—Tremor—Cisplatin—esophageal cancer	0.00407	0.00408	CcSEcCtD
Remifentanil—Renal failure—Capecitabine—esophageal cancer	0.00403	0.00404	CcSEcCtD
Remifentanil—Anaemia—Cisplatin—esophageal cancer	0.00401	0.00403	CcSEcCtD
Remifentanil—Haematuria—Capecitabine—esophageal cancer	0.00391	0.00392	CcSEcCtD
Remifentanil—Convulsion—Cisplatin—esophageal cancer	0.00376	0.00377	CcSEcCtD
Remifentanil—Bradycardia—Capecitabine—esophageal cancer	0.00374	0.00376	CcSEcCtD
Remifentanil—Haemoglobin—Capecitabine—esophageal cancer	0.0037	0.00371	CcSEcCtD
Remifentanil—Anxiety—Cisplatin—esophageal cancer	0.00368	0.0037	CcSEcCtD
Remifentanil—Haemorrhage—Capecitabine—esophageal cancer	0.00368	0.00369	CcSEcCtD
Remifentanil—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.00367	0.00368	CcSEcCtD
Remifentanil—Pharyngitis—Capecitabine—esophageal cancer	0.00365	0.00366	CcSEcCtD
Remifentanil—Oedema—Cisplatin—esophageal cancer	0.00354	0.00356	CcSEcCtD
Remifentanil—Anaphylactic shock—Cisplatin—esophageal cancer	0.00354	0.00356	CcSEcCtD
Remifentanil—Visual impairment—Capecitabine—esophageal cancer	0.00354	0.00356	CcSEcCtD
Remifentanil—Nervous system disorder—Cisplatin—esophageal cancer	0.00348	0.00349	CcSEcCtD
Remifentanil—Thrombocytopenia—Cisplatin—esophageal cancer	0.00347	0.00348	CcSEcCtD
Remifentanil—Tachycardia—Cisplatin—esophageal cancer	0.00346	0.00347	CcSEcCtD
Remifentanil—Skin disorder—Cisplatin—esophageal cancer	0.00344	0.00345	CcSEcCtD
Remifentanil—Hyperhidrosis—Cisplatin—esophageal cancer	0.00343	0.00344	CcSEcCtD
Remifentanil—Cardiac disorder—Capecitabine—esophageal cancer	0.00341	0.00342	CcSEcCtD
Remifentanil—Flushing—Capecitabine—esophageal cancer	0.00341	0.00342	CcSEcCtD
Remifentanil—Angiopathy—Capecitabine—esophageal cancer	0.00334	0.00335	CcSEcCtD
Remifentanil—Immune system disorder—Capecitabine—esophageal cancer	0.00332	0.00333	CcSEcCtD
Remifentanil—Mediastinal disorder—Capecitabine—esophageal cancer	0.00331	0.00332	CcSEcCtD
Remifentanil—Hypotension—Cisplatin—esophageal cancer	0.00331	0.00332	CcSEcCtD
Remifentanil—Chills—Capecitabine—esophageal cancer	0.0033	0.00331	CcSEcCtD
Remifentanil—Arrhythmia—Capecitabine—esophageal cancer	0.00329	0.0033	CcSEcCtD
Remifentanil—Abdominal discomfort—Methotrexate—esophageal cancer	0.00328	0.00329	CcSEcCtD
Remifentanil—Erythema—Capecitabine—esophageal cancer	0.0032	0.00321	CcSEcCtD
Remifentanil—Dysuria—Methotrexate—esophageal cancer	0.0032	0.00321	CcSEcCtD
Remifentanil—Paraesthesia—Cisplatin—esophageal cancer	0.00318	0.00319	CcSEcCtD
Remifentanil—Dyspnoea—Cisplatin—esophageal cancer	0.00316	0.00317	CcSEcCtD
Remifentanil—Pneumonia—Methotrexate—esophageal cancer	0.00307	0.00308	CcSEcCtD
Remifentanil—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00306	0.00307	CcSEcCtD
Remifentanil—Pain—Cisplatin—esophageal cancer	0.00303	0.00304	CcSEcCtD
Remifentanil—Tremor—Capecitabine—esophageal cancer	0.003	0.00301	CcSEcCtD
Remifentanil—Renal failure—Methotrexate—esophageal cancer	0.003	0.00301	CcSEcCtD
Remifentanil—Anaemia—Capecitabine—esophageal cancer	0.00296	0.00297	CcSEcCtD
Remifentanil—Sweating—Methotrexate—esophageal cancer	0.00292	0.00293	CcSEcCtD
Remifentanil—Feeling abnormal—Cisplatin—esophageal cancer	0.00292	0.00293	CcSEcCtD
Remifentanil—Haematuria—Methotrexate—esophageal cancer	0.00291	0.00292	CcSEcCtD
Remifentanil—Syncope—Capecitabine—esophageal cancer	0.00287	0.00288	CcSEcCtD
Remifentanil—Loss of consciousness—Capecitabine—esophageal cancer	0.00281	0.00282	CcSEcCtD
Remifentanil—Body temperature increased—Cisplatin—esophageal cancer	0.0028	0.00281	CcSEcCtD
Remifentanil—Cough—Capecitabine—esophageal cancer	0.00279	0.0028	CcSEcCtD
Remifentanil—Hypertension—Capecitabine—esophageal cancer	0.00276	0.00277	CcSEcCtD
Remifentanil—Haemoglobin—Methotrexate—esophageal cancer	0.00275	0.00276	CcSEcCtD
Remifentanil—Haemorrhage—Methotrexate—esophageal cancer	0.00274	0.00275	CcSEcCtD
Remifentanil—Pharyngitis—Methotrexate—esophageal cancer	0.00272	0.00273	CcSEcCtD
Remifentanil—Anxiety—Capecitabine—esophageal cancer	0.00272	0.00272	CcSEcCtD
Remifentanil—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.00271	0.00272	CcSEcCtD
Remifentanil—Dry mouth—Capecitabine—esophageal cancer	0.00267	0.00267	CcSEcCtD
Remifentanil—Visual impairment—Methotrexate—esophageal cancer	0.00264	0.00265	CcSEcCtD
Remifentanil—Confusional state—Capecitabine—esophageal cancer	0.00263	0.00264	CcSEcCtD
Remifentanil—Oedema—Capecitabine—esophageal cancer	0.00261	0.00262	CcSEcCtD
Remifentanil—Hypersensitivity—Cisplatin—esophageal cancer	0.00261	0.00262	CcSEcCtD
Remifentanil—Shock—Capecitabine—esophageal cancer	0.00257	0.00258	CcSEcCtD
Remifentanil—Nervous system disorder—Capecitabine—esophageal cancer	0.00256	0.00257	CcSEcCtD
Remifentanil—Thrombocytopenia—Capecitabine—esophageal cancer	0.00256	0.00257	CcSEcCtD
Remifentanil—Tachycardia—Capecitabine—esophageal cancer	0.00255	0.00256	CcSEcCtD
Remifentanil—Cardiac disorder—Methotrexate—esophageal cancer	0.00254	0.00255	CcSEcCtD
Remifentanil—Skin disorder—Capecitabine—esophageal cancer	0.00254	0.00255	CcSEcCtD
Remifentanil—Hyperhidrosis—Capecitabine—esophageal cancer	0.00253	0.00253	CcSEcCtD
Remifentanil—Angiopathy—Methotrexate—esophageal cancer	0.00248	0.00249	CcSEcCtD
Remifentanil—Immune system disorder—Methotrexate—esophageal cancer	0.00247	0.00248	CcSEcCtD
Remifentanil—Mediastinal disorder—Methotrexate—esophageal cancer	0.00247	0.00248	CcSEcCtD
Remifentanil—Chills—Methotrexate—esophageal cancer	0.00246	0.00246	CcSEcCtD
Remifentanil—Hypotension—Capecitabine—esophageal cancer	0.00244	0.00245	CcSEcCtD
Remifentanil—Diarrhoea—Cisplatin—esophageal cancer	0.00243	0.00243	CcSEcCtD
Remifentanil—Erythema—Methotrexate—esophageal cancer	0.00238	0.00239	CcSEcCtD
Remifentanil—Paraesthesia—Capecitabine—esophageal cancer	0.00235	0.00235	CcSEcCtD
Remifentanil—Dyspnoea—Capecitabine—esophageal cancer	0.00233	0.00234	CcSEcCtD
Remifentanil—Dyspepsia—Capecitabine—esophageal cancer	0.0023	0.00231	CcSEcCtD
Remifentanil—Alfentanil—ABCB1—esophageal cancer	0.00229	0.732	CrCbGaD
Remifentanil—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.00226	0.00226	CcSEcCtD
Remifentanil—Vomiting—Cisplatin—esophageal cancer	0.00225	0.00226	CcSEcCtD
Remifentanil—Rash—Cisplatin—esophageal cancer	0.00223	0.00224	CcSEcCtD
Remifentanil—Pain—Capecitabine—esophageal cancer	0.00223	0.00224	CcSEcCtD
Remifentanil—Constipation—Capecitabine—esophageal cancer	0.00223	0.00224	CcSEcCtD
Remifentanil—Dermatitis—Cisplatin—esophageal cancer	0.00223	0.00224	CcSEcCtD
Remifentanil—Anaemia—Methotrexate—esophageal cancer	0.0022	0.00221	CcSEcCtD
Remifentanil—Feeling abnormal—Capecitabine—esophageal cancer	0.00215	0.00216	CcSEcCtD
Remifentanil—Nausea—Cisplatin—esophageal cancer	0.00211	0.00211	CcSEcCtD
Remifentanil—Cough—Methotrexate—esophageal cancer	0.00208	0.00209	CcSEcCtD
Remifentanil—Urticaria—Capecitabine—esophageal cancer	0.00208	0.00208	CcSEcCtD
Remifentanil—Body temperature increased—Capecitabine—esophageal cancer	0.00207	0.00207	CcSEcCtD
Remifentanil—Convulsion—Methotrexate—esophageal cancer	0.00206	0.00207	CcSEcCtD
Remifentanil—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.00201	0.00202	CcSEcCtD
Remifentanil—Confusional state—Methotrexate—esophageal cancer	0.00196	0.00197	CcSEcCtD
Remifentanil—Anaphylactic shock—Methotrexate—esophageal cancer	0.00194	0.00195	CcSEcCtD
Remifentanil—Hypersensitivity—Capecitabine—esophageal cancer	0.00192	0.00193	CcSEcCtD
Remifentanil—Nervous system disorder—Methotrexate—esophageal cancer	0.00191	0.00191	CcSEcCtD
Remifentanil—Thrombocytopenia—Methotrexate—esophageal cancer	0.0019	0.00191	CcSEcCtD
Remifentanil—Skin disorder—Methotrexate—esophageal cancer	0.00189	0.0019	CcSEcCtD
Remifentanil—Hyperhidrosis—Methotrexate—esophageal cancer	0.00188	0.00189	CcSEcCtD
Remifentanil—Pruritus—Capecitabine—esophageal cancer	0.00185	0.00185	CcSEcCtD
Remifentanil—Hypotension—Methotrexate—esophageal cancer	0.00182	0.00182	CcSEcCtD
Remifentanil—Diarrhoea—Capecitabine—esophageal cancer	0.00179	0.00179	CcSEcCtD
Remifentanil—Paraesthesia—Methotrexate—esophageal cancer	0.00175	0.00175	CcSEcCtD
Remifentanil—Dyspnoea—Methotrexate—esophageal cancer	0.00173	0.00174	CcSEcCtD
Remifentanil—Somnolence—Methotrexate—esophageal cancer	0.00173	0.00173	CcSEcCtD
Remifentanil—Dizziness—Capecitabine—esophageal cancer	0.00173	0.00173	CcSEcCtD
Remifentanil—Dyspepsia—Methotrexate—esophageal cancer	0.00171	0.00172	CcSEcCtD
Remifentanil—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.00168	0.00168	CcSEcCtD
Remifentanil—Pain—Methotrexate—esophageal cancer	0.00166	0.00167	CcSEcCtD
Remifentanil—Vomiting—Capecitabine—esophageal cancer	0.00166	0.00167	CcSEcCtD
Remifentanil—Rash—Capecitabine—esophageal cancer	0.00165	0.00165	CcSEcCtD
Remifentanil—Dermatitis—Capecitabine—esophageal cancer	0.00165	0.00165	CcSEcCtD
Remifentanil—Headache—Capecitabine—esophageal cancer	0.00164	0.00164	CcSEcCtD
Remifentanil—Feeling abnormal—Methotrexate—esophageal cancer	0.0016	0.00161	CcSEcCtD
Remifentanil—Nausea—Capecitabine—esophageal cancer	0.00155	0.00156	CcSEcCtD
Remifentanil—Urticaria—Methotrexate—esophageal cancer	0.00155	0.00155	CcSEcCtD
Remifentanil—Body temperature increased—Methotrexate—esophageal cancer	0.00154	0.00154	CcSEcCtD
Remifentanil—Hypersensitivity—Methotrexate—esophageal cancer	0.00143	0.00144	CcSEcCtD
Remifentanil—Pruritus—Methotrexate—esophageal cancer	0.00138	0.00138	CcSEcCtD
Remifentanil—Diarrhoea—Methotrexate—esophageal cancer	0.00133	0.00133	CcSEcCtD
Remifentanil—Dizziness—Methotrexate—esophageal cancer	0.00129	0.00129	CcSEcCtD
Remifentanil—Vomiting—Methotrexate—esophageal cancer	0.00124	0.00124	CcSEcCtD
Remifentanil—Rash—Methotrexate—esophageal cancer	0.00123	0.00123	CcSEcCtD
Remifentanil—Dermatitis—Methotrexate—esophageal cancer	0.00123	0.00123	CcSEcCtD
Remifentanil—Headache—Methotrexate—esophageal cancer	0.00122	0.00122	CcSEcCtD
Remifentanil—Nausea—Methotrexate—esophageal cancer	0.00116	0.00116	CcSEcCtD
Remifentanil—Fentanyl—ABCB1—esophageal cancer	0.00084	0.268	CrCbGaD
